gemifloxacin (Factive)

Introduction

Tradename: Factive (FDA approved 2003)

Indications

• bacterial infections due to susceptible organisms
  • acute bronchitis or exacerbation
  • community-acquired pneumonia, including multidrug-resistant Streptococcus pneumonia

Contraindications

• NOT for use in urinary tract infections does not reach adequate concentrations in urine

Dosage

PO QD dosing, with or without meals

Antimicrobial activity

• Streptococcus pneumonia
• Klebsiella pneumoniae
• Mycoplasma pneumoniae
• Chlamydophila pneumoniae
• Haemophilus influenzae
• Moraxella catarrhalis

Adverse effects

• rash, maculopapular, non pruritic (3%)
  • more likely than other fluoroquinolones to cause rash
  • more likely if therapy > 7 days
  • more common in patients < 40 years of age & postmenopausal women on hormone replacement therapy

• drug adverse effects of fluoroquinolones

Drug interactions

• Al+3 or Mg+2-containing antiacids, Fe+2, multivitamins with minerals, sucralfate, Videx interfere with absorption; separate by 2-3 hours

• drug interaction(s) anticonvulsants with anti-bacterial agents
• drug interaction(s) of antibiotics with warfarin
• drug interaction(s) of theophylline with fluoroquinolone
• drug interaction(s) of beta-adrenergic receptor antagonists with quinolones
• drug interaction(s) of fluroquinolones with amiodarone
• drug interaction(s) of fluroquinolones with sulfonylureas
• drug interaction(s) of fluoroquinolones with hypoglycemic agents

Mechanism of action

• fluoroquinolone

More general terms

• fluoroquinolone

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=72938
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=219097
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3055173
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=166539